{"count": 29, "results": [{"_id": "36438823", "pmid": 36438823, "pmcid": "PMC9691898", "title": "X-box binding protein 1: A new metabolic mediator and drug target of metformin?", "journal": "Front Pharmacol", "authors": ["Lou K", "Sun P", "Zhang C", "Jiang Q", "Pang S"], "date": "2022-11-11T00:00:00Z", "doi": "10.3389/fphar.2022.1013218", "meta_date_publication": "2022", "meta_volume": "13", "meta_issue": "", "meta_pages": "1013218", "score": 50279.61, "text_hl": "Accumulating evidence has demonstrated that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ improved @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@. ", "citations": {"NLM": "Lou K, Sun P, Zhang C, Jiang Q, Pang S. X-box binding protein 1: A new metabolic mediator and drug target of metformin? Front Pharmacol. 2022;13():1013218. PMID: 36438823", "BibTeX": "@article{36438823, title={X-box binding protein 1: A new metabolic mediator and drug target of metformin?}, author={Lou K and Sun P and Zhang C and Jiang Q and Pang S}, journal={Front Pharmacol}, volume={13}, pages={1013218}}"}}, {"_id": "34582252", "pmid": 34582252, "title": "L-ergothioneine and metformin alleviates liver injury in experimental type-2 diabetic rats via reduction of oxidative stress, inflammation, and hypertriglyceridemia.", "journal": "Can J Physiol Pharmacol", "authors": ["Dare A", "Channa ML", "Nadar A"], "date": "2021-11-01T00:00:00Z", "doi": "10.1139/cjpp-2021-0247", "meta_date_publication": "2021 Nov", "meta_volume": "99", "meta_issue": "11", "meta_pages": "1137-1147", "score": 50255.086, "text_hl": "@CHEMICAL_Ergothioneine @CHEMICAL_MESH:D004880 @@@L-ergothioneine@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ alleviates @DISEASE_Liver_Failure @DISEASE_MESH:D017093 @@@liver injury@@@ in experimental @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type-2 diabetic@@@ @SPECIES_10116 @@@rats@@@ via reduction of oxidative stress, @DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammation@@@, and @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@.", "citations": {"NLM": "Dare A, Channa ML, Nadar A. L-ergothioneine and metformin alleviates liver injury in experimental type-2 diabetic rats via reduction of oxidative stress, inflammation, and hypertriglyceridemia. Can J Physiol Pharmacol. 2021 Nov;99(11):1137-1147. PMID: 34582252", "BibTeX": "@article{34582252, title={L-ergothioneine and metformin alleviates liver injury in experimental type-2 diabetic rats via reduction of oxidative stress, inflammation, and hypertriglyceridemia.}, author={Dare A and Channa ML and Nadar A}, journal={Can J Physiol Pharmacol}, volume={99}, number={11}, pages={1137-1147}}"}}, {"_id": "37668313", "pmid": 37668313, "title": "Metformin Prescription for U.S. Veterans with Prediabetes, 2010-2019.", "journal": "J Investig Med", "authors": ["Gulanski B", "Goulet J", "Radhakrishnan K", "Ko J", "Li Y", "Rajeevan N", "Lee KM", "Heberer K", "Lynch J", "Streja E", "Mutalik P", "Cheung KH", "Concato J", "Shih MC", "Lee J", "Aslan M"], "date": "2023-09-05T00:00:00Z", "doi": "10.1177/10815589231201141", "meta_date_publication": "2023 Sep 5", "meta_volume": "", "meta_issue": "", "meta_pages": "10815589231201141", "score": 50253.047, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Prescription for U.S. ", "citations": {"NLM": "Gulanski B, Goulet J, Radhakrishnan K, Ko J, Li Y, Rajeevan N, Lee KM, Heberer K, Lynch J, Streja E, Mutalik P, Cheung KH, Concato J, Shih MC, Lee J, Aslan M. Metformin Prescription for U.S. Veterans with Prediabetes, 2010-2019. J Investig Med. 2023 Sep 5;():10815589231201141. PMID: 37668313", "BibTeX": "@article{37668313, title={Metformin Prescription for U.S. Veterans with Prediabetes, 2010-2019.}, author={Gulanski B and Goulet J and Radhakrishnan K and Ko J and Li Y and Rajeevan N and Lee KM and Heberer K and Lynch J and Streja E and Mutalik P and Cheung KH and Concato J and Shih MC and Lee J and Aslan M}, journal={J Investig Med}, pages={10815589231201141}}"}}, {"_id": "35986566", "pmid": 35986566, "pmcid": "PMC9470898", "title": "Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice", "journal": "Aging Cell", "authors": ["Reifsnyder PC", "Flurkey K", "Doty R", "Calcutt NA", "Koza RA", "Harrison DE"], "date": "2022-09-01T00:00:00Z", "doi": "10.1111/acel.13666", "meta_date_publication": "2022 Sep", "meta_volume": "21", "meta_issue": "9", "meta_pages": "e13666", "score": 50246.2, "text_hl": "In liver, the addition of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ counteracted @CHEMICAL_Sirolimus @CHEMICAL_MESH:D020123 @@@rapamycin@@@-induced alterations of @GENE_G6PC @GENE_14377 @@@G6pc@@@, @GENE_PPARA @GENE_19013 @@@Ppara@@@, and @GENE_LDLR @GENE_16835 @@@Ldlr@@@ expressions that promote @DISEASE_Hyperglycemia @DISEASE_MESH:D006943 @@@hyperglycemia@@@ and @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@. ", "citations": {"NLM": "Reifsnyder PC, Flurkey K, Doty R, Calcutt NA, Koza RA, Harrison DE. Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice Aging Cell. 2022 Sep;21(9):e13666. PMID: 35986566", "BibTeX": "@article{35986566, title={Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice}, author={Reifsnyder PC and Flurkey K and Doty R and Calcutt NA and Koza RA and Harrison DE}, journal={Aging Cell}, volume={21}, number={9}, pages={e13666}}"}}, {"_id": "39787747", "pmid": 39787747, "title": "A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer.", "journal": "Gynecol Oncol", "authors": ["Ahmed J", "Stephen B", "Khawaja MR", "Yang Y", "Salih I", "Barrientos-Toro E", "Raso MG", "Karp DD", "Piha-Paul SA", "Sood AK", "Ng CS", "Johnson A", "Soliman PT", "Meric-Bernstam F", "Lu KH", "Naing A"], "date": "2025-01-08T00:00:00Z", "doi": "10.1016/j.ygyno.2024.12.019", "meta_date_publication": "2025 Jan 8", "meta_volume": "193", "meta_issue": "", "meta_pages": "73-80", "score": 50245.15, "text_hl": "In addition to inducing metabolic changes in cells, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ activates @GENE_PRKAA2 @GENE_5563 @@@AMPK@@@, which in turn inhibits the @GENE_MTOR @GENE_2475 @@@mTOR@@@ pathway. ", "citations": {"NLM": "Ahmed J, Stephen B, Khawaja MR, Yang Y, Salih I, Barrientos-Toro E, Raso MG, Karp DD, Piha-Paul SA, Sood AK, Ng CS, Johnson A, Soliman PT, Meric-Bernstam F, Lu KH, Naing A. A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer. Gynecol Oncol. 2025 Jan 8;193():73-80. PMID: 39787747", "BibTeX": "@article{39787747, title={A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer.}, author={Ahmed J and Stephen B and Khawaja MR and Yang Y and Salih I and Barrientos-Toro E and Raso MG and Karp DD and Piha-Paul SA and Sood AK and Ng CS and Johnson A and Soliman PT and Meric-Bernstam F and Lu KH and Naing A}, journal={Gynecol Oncol}, volume={193}, pages={73-80}}"}}, {"_id": "33800673", "pmid": 33800673, "pmcid": "PMC8037495", "title": "Antidiabetic and Renoprotective Effects of Coffea arabica Pulp Aqueous Extract through Preserving Organic Cation Transport System Mediated Oxidative Stress Pathway in Experimental Type 2 Diabetic Rats", "journal": "Molecules", "authors": ["Boonphang O", "Ontawong A", "Pasachan T", "Phatsara M", "Duangjai A", "Amornlerdpison D", "Jinakote M", "Srimaroeng C"], "date": "2021-03-28T00:00:00Z", "doi": "10.3390/molecules26071907", "meta_date_publication": "2021 Mar 28", "meta_volume": "26", "meta_issue": "7", "meta_pages": "", "score": 50243.94, "text_hl": "Significant @DISEASE_Hyperglycemia @DISEASE_MESH:D006943 @@@hyperglycemia@@@, @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@, @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@insulin resistance@@@, increased renal @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@ content and @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@ peroxidation, and morphological kidney changes related to @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2D@@@ were restored by both CPE and CPE + @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Met@@@ treatments. ", "citations": {"NLM": "Boonphang O, Ontawong A, Pasachan T, Phatsara M, Duangjai A, Amornlerdpison D, Jinakote M, Srimaroeng C. Antidiabetic and Renoprotective Effects of Coffea arabica Pulp Aqueous Extract through Preserving Organic Cation Transport System Mediated Oxidative Stress Pathway in Experimental Type 2 Diabetic Rats Molecules. 2021 Mar 28;26(7):. PMID: 33800673", "BibTeX": "@article{33800673, title={Antidiabetic and Renoprotective Effects of Coffea arabica Pulp Aqueous Extract through Preserving Organic Cation Transport System Mediated Oxidative Stress Pathway in Experimental Type 2 Diabetic Rats}, author={Boonphang O and Ontawong A and Pasachan T and Phatsara M and Duangjai A and Amornlerdpison D and Jinakote M and Srimaroeng C}, journal={Molecules}, volume={26}, number={7}}"}}, {"_id": "35821558", "pmid": 35821558, "title": "Lipodystrophy for the Diabetologist-What to Look For.", "journal": "Curr Diab Rep", "authors": ["Patni N", "Garg A"], "date": "2022-09-01T00:00:00Z", "doi": "10.1007/s11892-022-01485-w", "meta_date_publication": "2022 Sep", "meta_volume": "22", "meta_issue": "9", "meta_pages": "461-470", "score": 50240.05, "text_hl": "Metreleptin should be considered as the first-line therapy for metabolic complications in @SPECIES_9606 @@@patients@@@ with generalized @DISEASE_Lipodystrophy @DISEASE_MESH:D008060 @@@lipodystrophy@@@ and for prevention of comorbidities in children. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and @CHEMICAL_Insulin @CHEMICAL_MESH:D007328 @@@insulin@@@ therapy are the best options for treating @DISEASE_Hyperglycemia @DISEASE_MESH:D006943 @@@hyperglycemia@@@ and @CHEMICAL_Fibric_Acids @CHEMICAL_MESH:D058607 @@@fibrates@@@ and/or fish oil for @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@. ", "citations": {"NLM": "Patni N, Garg A. Lipodystrophy for the Diabetologist-What to Look For. Curr Diab Rep. 2022 Sep;22(9):461-470. PMID: 35821558", "BibTeX": "@article{35821558, title={Lipodystrophy for the Diabetologist-What to Look For.}, author={Patni N and Garg A}, journal={Curr Diab Rep}, volume={22}, number={9}, pages={461-470}}"}}, {"_id": "32371063", "pmid": 32371063, "title": "NLRP3 inflammasome drives inflammation in high fructose fed diabetic rat liver: Effect of resveratrol and metformin.", "journal": "Life Sci", "authors": ["Rai RC", "Bagul PK", "Banerjee SK"], "date": "2020-07-15T00:00:00Z", "doi": "10.1016/j.lfs.2020.117727", "meta_date_publication": "2020 Jul 15", "meta_volume": "253", "meta_issue": "", "meta_pages": "117727", "score": 50239.855, "text_hl": "Mostly, above parameters were attenuated in @CHEMICAL_Resveratrol @CHEMICAL_MESH:D000077185 @@@resveratrol@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treated groups. ", "citations": {"NLM": "Rai RC, Bagul PK, Banerjee SK. NLRP3 inflammasome drives inflammation in high fructose fed diabetic rat liver: Effect of resveratrol and metformin. Life Sci. 2020 Jul 15;253():117727. PMID: 32371063", "BibTeX": "@article{32371063, title={NLRP3 inflammasome drives inflammation in high fructose fed diabetic rat liver: Effect of resveratrol and metformin.}, author={Rai RC and Bagul PK and Banerjee SK}, journal={Life Sci}, volume={253}, pages={117727}}"}}, {"_id": "36251589", "pmid": 36251589, "title": "Tert-butylhydroquinone abrogates fructose-induced insulin resistance in rats via mitigation of oxidant stress, NFkB-mediated inflammation in the liver but not the skeletal muscle of high fructose drinking rats.", "journal": "J Food Biochem", "authors": ["Eleazu CO", "Obeten UN", "Ozor G", "Njemanze CC", "Eleazu KC", "Egedigwe-Ekeleme AC", "Okorie UC", "Ogunwa SC", "Adeolu AI", "Okoh PN", "Kalu AO", "Onyia CJ", "Onyia S", "Ossai P", "Chikezie CC", "Odii BC", "Obi V", "Igwe VM", "Amobi CA", "Ugada OJ", "Kalu WO", "Kanu S"], "date": "2022-12-01T00:00:00Z", "doi": "10.1111/jfbc.14473", "meta_date_publication": "2022 Dec", "meta_volume": "46", "meta_issue": "12", "meta_pages": "e14473", "score": 50237.97, "text_hl": "FDW changed the serum @GENE_LEP @GENE_25608 @@@leptin@@@, @CHEMICAL_Triglycerides @CHEMICAL_MESH:D014280 @@@triacylglycerol@@@, very low-density lipoprotein, and @GENE_CRP @GENE_25419 @@@C-reactive protein@@@ levels of the @SPECIES_10116 @@@rats@@@, inducing @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@, oxidative stress, and @DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammation@@@ in their liver (but not the skeletal muscle) and @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@insulin resistance@@@ which were modulated with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and @CHEMICAL_2_tert_butylhydroquinone @CHEMICAL_MESH:C018855 @@@tBHQ@@@ as corroborated by liver and muscle histology. ", "citations": {"NLM": "Eleazu CO, Obeten UN, Ozor G, Njemanze CC, Eleazu KC, Egedigwe-Ekeleme AC, Okorie UC, Ogunwa SC, Adeolu AI, Okoh PN, Kalu AO, Onyia CJ, Onyia S, Ossai P, Chikezie CC, Odii BC, Obi V, Igwe VM, Amobi CA, Ugada OJ, Kalu WO, Kanu S. Tert-butylhydroquinone abrogates fructose-induced insulin resistance in rats via mitigation of oxidant stress, NFkB-mediated inflammation in the liver but not the skeletal muscle of high fructose drinking rats. J Food Biochem. 2022 Dec;46(12):e14473. PMID: 36251589", "BibTeX": "@article{36251589, title={Tert-butylhydroquinone abrogates fructose-induced insulin resistance in rats via mitigation of oxidant stress, NFkB-mediated inflammation in the liver but not the skeletal muscle of high fructose drinking rats.}, author={Eleazu CO and Obeten UN and Ozor G and Njemanze CC and Eleazu KC and Egedigwe-Ekeleme AC and Okorie UC and Ogunwa SC and Adeolu AI and Okoh PN and Kalu AO and Onyia CJ and Onyia S and Ossai P and Chikezie CC and Odii BC and Obi V and Igwe VM and Amobi CA and Ugada OJ and Kalu WO and Kanu S}, journal={J Food Biochem}, volume={46}, number={12}, pages={e14473}}"}}, {"_id": "35735786", "pmid": 35735786, "pmcid": "PMC10448557", "title": "Metreleptin Treatment in a Boy with Congenital Generalized Lipodystrophy due to Homozygous c.465_468delGACT (p.T156Rfs*8) Mutation in the BSCL2 Gene: Results From the First-year", "journal": "J Clin Res Pediatr Endocrinol", "authors": ["Özalkak Ş", "Demiral M", "Ünal E", "Taş FF", "Onay H", "Demirbilek H", "Özbek MN"], "date": "2022-06-23T00:00:00Z", "doi": "10.4274/jcrpe.galenos.2022.2022-1-25", "meta_date_publication": "2022 Jun 23", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50237.293, "text_hl": "Despite dietary intervention, exercise, and treatment with additional omega-3 and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, the @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@, @DISEASE_Hyperinsulinism @DISEASE_MESH:D006946 @@@hyperinsulinemia@@@, and elevated liver transaminase levels worsened. ", "citations": {"NLM": "Özalkak Ş, Demiral M, Ünal E, Taş FF, Onay H, Demirbilek H, Özbek MN. Metreleptin Treatment in a Boy with Congenital Generalized Lipodystrophy due to Homozygous c.465_468delGACT (p.T156Rfs*8) Mutation in the BSCL2 Gene: Results From the First-year J Clin Res Pediatr Endocrinol. 2022 Jun 23;():. PMID: 35735786", "BibTeX": "@article{35735786, title={Metreleptin Treatment in a Boy with Congenital Generalized Lipodystrophy due to Homozygous c.465_468delGACT (p.T156Rfs*8) Mutation in the BSCL2 Gene: Results From the First-year}, author={Özalkak Ş and Demiral M and Ünal E and Taş FF and Onay H and Demirbilek H and Özbek MN}, journal={J Clin Res Pediatr Endocrinol}}"}}]}